The Omicron BA.2 variant has become a dominant infective strain worldwide. Receptor binding studies show that the Omicron BA.2 spike trimer exhibits 11-fold and 2-fold higher potency in binding to human ACE2 than the spike trimer from the wildtype (WT) and Omicron BA.1 strains. The structure of the BA.2 spike trimer complexed with human ACE2 reveals that all three receptor-binding domains (RBDs) in the spike trimer are in open conformation, ready for ACE2 binding, thus providing a basis for the increased infectivity of the BA.2 strain. JMB2002, a therapeutic antibody that was shown to efficiently inhibit Omicron BA.1, also shows potent neutralization activities against Omicron BA.2. In addition, both BA.1 and BA.2 spike trimers are able to bind to mouse ACE2 with high potency. In contrast, the WT spike trimer binds well to cat ACE2 but not to mouse ACE2. The structures of both BA.1 and BA.2 spike trimer bound to mouse ACE2 reveal the basis for their high affinity interactions. Together, these results suggest a possible evolution pathway for Omicron BA.1 and BA.2 variants via a human-cat-mouse-human circle, which could have important implications in establishing an effective strategy for combating SARS-CoV-2 viral infections.
The Omicron variants BA.1 and BA.2 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of COVID-19, are two sister variants of concerns (VOCs) that have infected hundreds of millions of people worldwide.1 In particular, the BA.2 strain has overtaken the BA.1 strain to become the current dominant infective strain that continues to rampage across the globe (Fig. 1a).2 Both BA.1 and BA.2 strains are evolved independently from predominant VOC strains, including Alpha, Beta, Gamma, and Delta variants.3 Mutational profile analysis suggests that the Omicron variants may arise from evolution through mouse as a host.4 The biochemical and structural basis for the viral infection to mouse remains largely unknown.
The trimeric spike protein is a major membrane surface glycoprotein of SARS-CoV-2 that mediates the binding to the host receptor ACE2 and subsequent viral entry into cells.5,6,7 The matured spike protein contains two subunits: an ACE2-binding S1 subunit and a membrane-fusion S2 subunit. Within the S1 subunit is an N-terminal domain (NTD) of unknown function and a C-terminal receptor-binding domain (RBD). The S2 subunit contains a conserved fusion peptide (FP) motif that is mostly hydrophobic and capable of mediating viral fusion with host cells.7 Extensive structures of the spike trimer reveal the open and closed conformations for the three RBDs within the spike trimer, where the open “up” RBD conformation is prerequisite for ACE2 binding.3,6,8,9,10,11,12 Upon ACE2 binding, the spike trimer undergoes conformational changes to expose the FP motif of the S2 subunit to initiate membrane fusion that allows the release of the viral genome into host cells.13
The spike protein is also the major target of immune response to infection, vaccination, and antibody therapy.14,15,16,17,18 Most VOCs such as the Delta variant contain 7–10 mutations in the spike protein. In contrast, Omicron BA.1 and BA.2 have 37 and 31 mutations in their spike protein, respectively.19 Structural studies of the Omicron BA.1 spike trimer reveal that most of the 37 mutations are mapped on the surface of the spike protein, with many of them enriched in known epitopes of therapeutic antibodies.3,20,21,22 In addition, the Omicron BA.1 spike protein binds to the human ACE2 with 6–7 fold higher potency than WT spike and the Omicron BA.1 spike trimer is less stable and prone to the open “up” conformation that is ready to interact with ACE2.3 These studies have provided the molecular basis for the increased infectivity and immune evasion of Omicron BA.1 to vaccination and antibody therapy. However, the Omicron BA.2 variant is even more contagious and has surpassed BA.1 as the dominant infective strain currently in many regions across the world (Fig. 1a).2 The Omicron BA.2 spike protein has 22 amino acid differences from the BA.1 spike protein (Supplementary information, Fig. S1), more than 7 amino acid differences of the Delta variant from the original WT strain.
Although the symptoms of infection by Omicron BA.1 and BA.2 appear to be less severe,23,24 antibody therapy may be essential for critically ill patients. JMB2002, a broad-spectrum therapeutic antibody, is known to inhibit both the WT strain and the Omicron BA.1 variant.3,25 However, the efficacy of JMB2002 against the Omicron BA.2 is unknown. In this work, we report the cryo-EM structures of the Omicron BA.2 spike trimer in complex with the human ACE2 and JMB2002. We also determined the spike trimer from both BA.1 and BA.2 in complex with the mouse ACE2. Together with comprehensive biochemical studies, our structures provide a basis for the higher transmission and immune evasion of the Omicron BA.2 variant and possible mouse origins of Omicron BA.1 and BA.2 variants.
Characterization of the interaction of the Omicron BA.2 spike trimer with hACE2
To study the mechanism for enhanced transmission of Omicron BA.2, we first characterized the interaction between the human ACE2 (hACE2) with the spike extracellular domain trimer from SARS-CoV-2 Omicron BA.2, BA.1, and WT strains, all of which contain mutations in the furin cleavage site and proline substitutions (2 P or 6 P) to stabilize the prefusion conformation. Dimeric hACE2 bound to Omicron BA.2 spike trimer with a dissociation constant (KD) value of 0.4 ± 0.1 nM, which is approximately 11-fold higher than that with WT spike trimer (KD = 4.7 ± 0.6 nM) and is nearly 2-fold higher than that with BA.1 spike trimer (KD = 0.75 ± 0.1 nM) (Fig. 1b, c). We also examined the interaction of monomeric hACE2 with Omicron BA.2 spike trimer with the KD value of 3.2 ± 0.7 nM, which is approximately 5-fold higher than that with WT spike trimer (KD = 15.0 ± 0.6 nM) and is around 2-fold higher than that with BA.1 spike trimer (KD = 6.4 ± 1.0 nM) (Supplementary information, Fig. S2). The observed interactions between hACE2 and WT spike trimer, and between hACE2 and BA.1 spike trimer were consistent with previously published data.3 The enhanced interaction of Omicron BA.2 spike trimer protein with hACE2 may be one of the key factors that contribute to the increased transmissibility of the BA.2 strain.
To gain structural insights into the potent binding of the Omicron BA.2 spike trimer to hACE2, we reconstituted the Omicron BA.2 spike trimer-hACE2 complex with an excess of hACE2, followed by size exclusion chromatography and cryo-electron microscopy (cryo-EM) analysis (Supplementary information, Figs. S3, S4, and Table S1). We observed two distinct structure states of the BA.2 spike trimer-hACE2 complex (Fig. 1d, e). In the first state, each spike molecule from the BA.2 spike trimer binds to one hACE2 molecule and all three RBDs are in an open up position for hACE2 binding (3-hACE2-bound BA.2 structure) (Fig. 1d). In the second structure state, two of three RBDs are in the open up position, both of which bind to hACE2 (2-hACE2-bound BA.2 structure). The third RBD is in a clear down position and shows the direct interaction with an up RBD, as it was observed previously (Fig. 1e).3 Particle classification reveals that about 42% and 58% spike particles bind with hACE2 in 3:3 and 3:2 molar ratio, respectively, albeit an excess of hACE2 were incubated with spike trimer during sample preparation. Notably, only one hACE2 bound to one RBD from the spike trimer was observed in our previous cryo-EM structural analysis of Omicron BA.1 spike trimer-hACE2 complex.3 In contrast, in the Omicron BA.2 spike trimer-hACE2 complex, the spike trimer bound to at least two or three hACE2, indicating a stronger hACE2-binding tendency of the BA.2 spike trimer.
Mapping the 31 mutations onto the Omicron BA.2 spike trimer reveals that 23 mutations are distributed on the surface and 3 are on the interior of the spike trimer (Fig. 1f). 22 out of 31 mutations are different from BA.1, while the rest of the mutations share the same substitutes with BA.1. Similar with 15 mutations in the RBD of BA.1 spike, 16 mutations are located on the RBD domain of BA.2 spike (Fig. 1g), which serves as ACE2 binding and the epitopes for 90% of antibodies.3,26,27,28 These mutations could cause the immune evasion to vaccines and therapeutic antibodies,29 however, some antibodies that do not rely on those sites could retain the immunity.
Focus refinement on RBD-hACE2 region resulted a reconstruction map at 3.0 Å resolution (Supplementary information, Fig. S4). The cryo-EM density map was of sufficient quality to enable us to build an atomic model of the RBD-hACE2 structure (Fig. 2a). The overall assembly of the Omicron BA.2 RBD-hACE2 complex closely resembles the Omicron BA.1 RBD-hACE2 complex, where the receptor binding motif (RBM) is identical. Briefly, the side chain of Q493R forms a new salt bridge with E35 of hACE2, Q498R forms a new salt bridge with D38 of hACE2, and K417N loses a salt bridge (Fig. 2b, c), these key mutations resulted in an enhanced binding to hACE2. Thermal shift assays showed that the spike trimers from Omicron BA.2, Omicron BA.1, and WT displayed two melting temperatures, which were assigned previously, with the lower Tm for the RBD and the higher Tm for the spike trimer.3 The Tm values for the RBD from Omicron BA.2, Omicron BA.1, and WT are 47.4 °C, 44.5 °C, and 52.5 °C, respectively (Fig. 2d), indicating that RBD in Omicron BA.2 is more stable than that from BA.1, but less stable than the WT. In the BA.2 RBD, the substitute of D405, N405 forms two inter-molecular hydrogen bonds with the side chain of R403 and the main chain of G504 (Fig. 2e). The BA.1 RBD lacks these interactions because the distance between the side chain of D405 and R403 is about 4.5 Å (Fig. 2e). The additional interactions in the BA.2 RBD above could contribute to its higher stability than the BA.1 RBD. The lower Tm2, which corresponds to the dissociation of the BA.2 spike trimer, indicates its more dynamic nature than BA.1 spike trimer (Fig. 2d). The BA.1 and BA.2 spike trimers are different in three additional residues, including T547K in the S1 region, D856K and L981F in S2 region. These mutations are found in the BA.1 spike but not in the BA.2 spike. Among the three different residues, D856K in BA.1 from protomer 1 forms a salt bridge with D571 from the adjacent protomer, which could stabilize the BA.1 spike trimer (Fig. 2e). In BA.2 strain, D856 lacks such interaction, and thus, the BA.2 spike trimer shows lower melting temperature under our thermal shift assays.
Inhibition of ACE2 binding to the BA.2 spike trimer by an anti-Omicron antibody JMB2002
Previously, we reported the potent neutralization activity of a clinical stage antibody, JMB2002, which could effectively neutralize Omicron BA.1 as well as variants Alpha, Beta, and Gamma, but not Delta.3,25 To evaluate the neutralizing activity of JMB2002 against the Omicron BA.2 variant, we first evaluated the binding of JMB2002 to the Omicron BA.2 spike trimer. JMB2002 Fab recognized the Omicron BA.2 spike trimer with KD of approximately 2.6 nM. Meanwhile, JMB2002 IgG bound to the Omicron BA.2 spike trimer with KD of approximately 0.3 nM (Fig. 3a). The potency of JMB2002 to the Omicron BA.2 spike trimer is similar to the Omicron BA.1 spike trimer, despite about 22 different mutations between the spike protein of BA.2 and BA.1. As we would expect, JMB2002 effectively blocked the entry of the Omicron BA.2 pseudovirus into human ACE2-expressing cells in a pseudovirus neutralization assay, with the half-maximal inhibition concentration (IC50) of 0.2 μg/mL (Fig. 3b), which is the same as for the inhibition of Omicron BA.1 pseudovirus. Taken together, JMB2002 is a broad-spectrum anti-SARS-CoV-2 antibody that has equal inhibition efficacy against both Omicron BA.1 and BA.2 strains.
To explore the basis of JMB2002 inhibition of Omicron BA.2, we solved the structure of the Omicron BA.2 spike trimer bound to a Fab from JMB2002 at a global resolution of 3.27 Å (Fig. 3c; Supplementary information, Fig. S5 and Table S1), with the aid of the same nanobody to stabilize the constant regions of Fab as we used in the Omicron BA.1 study.3 The cryo-EM density map reveals the binding of three Fab molecules, with each RBD (two RBDs up and one RBD down) bound to a Fab (labeled as RBD-1-3 and Fab-1-3 in Fig. 3c, d), which was also similar to one of our previously solved structures of JMB2002 Fab bound to the Omicron BA.1 spike trimer.3 Superposition of the structure of Fab-bound Omicron BA.2 spike trimer with the 3-hACE2-bound BA.2 structure demonstrated that Fab-1 binding to the down RBD-1 would clash with hACE2-1 and hACE2-2, while Fab-3 binding to the up RBD-3 would clash with hACE2-3 (Fig. 3e). Thus, the binding of three Fabs to the spike trimer would completely block ACE2 binding.
Cross-species binding of ACE2 with the Omicron spike trimer
Omicron variants have been proposed to evolve independently from previous VOCs and their origins are elusive.3 To investigate the potential evolution roadmap of Omicron variants, we evaluated the cross-species ACE2 binding to the spike trimer from WT and Omicron BA.1 and BA.2 strains. Unlike human ACE2, which showed enhanced binding to the Omicron spike trimer, ACE2 from horse, pig, and sheep displayed decreased binding, with cat ACE2 protein showing similar binding between WT and Omicron variants (Supplementary information, Fig. S2). Meanwhile, both the rat and dog ACE2 showed no binding with WT, Omicron BA.1, or Omicron BA.2 trimers (Supplementary information, Fig. S2). To our surprise, we found that mouse ACE2 bound to both Omicron BA.1 and BA.2 spike trimer with high affinity (Fig. 4a, b), but no binding to WT spike trimer (Fig. 4c). Moreover, mouse ACE2 binds to the Omicron BA.2 spike trimer with approximately threefold increased affinity (KD = 2.9 ± 0.2 nM) over the Omicron BA.1 spike trimer (KD = 9.1 ± 7.1 nM) (Fig. 4a, b, d).
Multiple sequence alignment reveals that 7 out of 16 key interface residues of ACE2 residues involved in interactions with the SARS-CoV-2 spike trimer are highly conserved in human, mouse, cat, rat, and dog, which include S19, F28, E35, Y41, Q42, L45, and D355 (Fig. 4e; Supplementary information, Fig. S2). The rest 9 residues varied from species to species, thus leading to a diverse binding behavior to the SARS-CoV-2 spike trimer. A homology model of cat ACE2 bound to the BA.2 RBD, based on the solved BA.2 RBD in this work and cat ACE2 structure (Fig. 4f),30 revealed that cat ACE2 can make the similar hydrogen bonds with RBDs from WT and both Omicron strains, resulting in comparable binding activity. However, homologous ACE2 residues from dog (L24, Y34, and E38) and rat (K24, Q34, and F83) cannot make similar interactions to the BA.2 RBD, leading to no binding to the BA.2 spike trimer, consistent with our binding data (Fig. 4d, e, g, h; Supplementary information, Fig. S2). In aggregate, our results show the determinant residues of ACE2 for cross-species specificity.
Cryo-EM Structures of BA.2 and BA.1 spike trimer binding with mACE2
To reveal the molecular basis for the high affinity binding of the Omicron BA.2 and BA.1 spike trimer to mouse ACE2, we determined their complex structures (Fig. 5a–d; Supplementary information, Figs. S6, S7 and Table S1). Two major states were observed for both BA.2-mACE2 and BA.1-mACE2 complexes, in which the spike trimer binds to one or two mACE2. In the first state, one RBD is in the open up position with mACE2 binding, and the other two RBDs are in the close down conformation without mACE2 binding (Fig. 5a, c). The second state is with two RBDs in the open up position with mACE2 binding, and the third RBD is in the close down position without mACE2 binding (Fig. 5b, d). We observed similar RBD-RBD interactions in all mACE2 complexes with the spike trimer of BA.1 and BA.2, which is consistent with the similar interaction in Omicron spike trimer-hACE2 complexes. A BA.2-mACE2 complex structure with all three RBDs bound to mACE2 in the open up conformation was also obtained at 4.5 Å resolution upon further particle classification (Supplementary information, Fig. S6e). Local refinement of the RBD-ACE2 region produced a high-quality map of BA.2 RBD-mACE2 and BA.1 RBD-mACE2 at 2.37 Å and 3.01 Å resolution, respectively, which allowed unambiguous model buildings of the RBD-mACE2 complexes (Fig. 5e, f; Supplementary information, Figs. S6, S7). Structure comparison of the BA.2 RBD-mACE2 complex with the BA.1 RBD-mACE2 complex shows a similar overall organization, which also resembles the Omicron RBD-hACE2 complexes.
Molecular interactions between mouse ACE2 and Omicron RBDs
The high affinity binding of mACE2 to both BA.2 and BA.1 spike trimers can be rationalized with the extensive interactions between mACE2 and the RBDs from both Omicron strains. In the BA.2 RBD-mACE2 structure, Y449 of BA.2 RBD forms two hydrogen bonds with D38 and Q42 of mACE2, N487 of BA.2 RBD forms a hydrogen bond with N24 of mACE2, while T500 of BA.2 RBD forms two hydrogen bonds with Y41 and D355 of mACE2 (Fig. 6a, b). Meanwhile, the BA.2 RBD forms additional interactions with mACE2 from the mutated residues. Particularly, Q493R forms three hydrogen bonds with N31 and Q34, and a salt bridge with E35 of mACE2; Q498R forms a salt bridge with D38, and a hydrogen bond with Q42 of mACE2; while N501Y forms extensive π-π stacking interactions with H353 of mACE2 (Fig. 6a, b). The interactions of BA.1 RBD with mACE2 closely resemble those in the BA.2 RBD-mACE2 complex (Fig. 6c, d). The interactions of the RBDs from both Omicron strains with mACE2 cannot be completely satisfied in the hypothetical model of the WT RBD-mACE2 complex (Fig. 6e, f), which are consistent with our binding assays that the WT RBD cannot bind to mACE2. Collectively, our results indicate that the three mutations of Q493R, Q498R, and N501Y in the Omicron RBDs are essential for mACE2 binding.
Given that ACE2 is highly conserved among mammals including mouse and human, we aligned the two structures of BA.2 RBD-hACE2 and BA.2 RBD-mACE2 with the root mean square deviation of 0.48 Å for 670 Cα atoms from both RBD and ACE2. Detailed structural analysis reveals a similar interaction network from mACE2 and hACE2 to the BA.2 RBD (Fig. 7a, b), supporting that both mACE2 and hACE2 bind to the BA.2 RBD with high affinity.
BA.2, a new variant of Omicron, has rapidly spread throughout the world and has become the dominant strain due to its higher infectivity than BA.1. In this study, we first biochemically analyzed the binding affinity of the BA.2 spike trimer to hACE2, which showed around 2-fold higher affinity than that of BA.1 and 11-fold higher affinity than that of the WT strain. The spike-ACE2 interaction is the first step of viral binding to host cells, which is critically important for viral entry and subsequent infections. Thus, the higher binding potency of the BA.2 spike trimer likely contributes to its higher transmission capability although many other factors such as spike trimer could also contribute to viral entry and infectivity. The structure of the BA.2 spike trimer with hACE2 reveals an extensive interaction network in the RBD-hACE2 interface, which is also conserved in the BA.1 spike trimer-hACE2 complex. The network of interaction of the BA.2 spike trimer with hACE2 is more extensive than the WT spike trimer-ACE2 complex, providing a structural basis for the high binding potency of the BA.2 spike trimer to hACE2. In addition, the RBD of BA.2 is more stable than the BA.1 RBD because of an additional interaction of R403 with D405N in BA.2, which is missing in BA.1 (Fig. 1e). The higher stability of the BA.2 RBD than that of the BA.1 RBD might also contribute to the higher binding affinity of the BA.2 RBD to hACE2 because the high stability of the structure reduces the binding energy cost associated with entropy loss upon binding.
Like the BA.1 strain, BA.2 also harbors many mutations that help its decreased sensitivity to many neutralizing monoclonal antibodies (mAbs). In addition, 4 missense mutations of S371F, T376A, D405N, and R408S in BA.2 RBD but not in BA.1 RBD could also potentially increase the immune evasion of neutralizing antibodies and vaccination, which brings even more challenges to effectively subdue the current COVID-19 pandemic. On the other hand, the spike protein of both BA.1 and BA.2 has 37 and 31 mutations out of 1273 residues, respectively, representing less than 3% of total mass. Although most Omicron mutations are clustered on the epitopes to many neutralizing mAbs, the majority of the spike protein surface resembles the WT spike protein (Fig. 1f, g). Using the WT spike protein as the antigen for vaccines can induce B cell and T cell responses,31 which could recognize the overall structures of the spike trimer as well as other conserved regions outside of the hot epitope regions. Although vaccination with the WT spike protein as antigen as used in many current vaccines cannot completely block Omicron infections, it can reduce severity of Omicron infection, possibly through the remaining immunity induced by the WT spike protein.
Despite less severe symptoms in the general population infected with Omicron variants, immunocompromised people with underlying diseases are still at high risk of developing severe forms of COVID-19. Antibody therapy could serve as a viable option for these patients either as a preventive treatment or a therapeutic option. However, several mAbs available in clinical practice have shown decreased potency to Omicron BA.1 and BA.2 variants.32 Thus, broad-spectrum anti-SARS-CoV-2 antibodies, especially with potent activities against Omicron variants are currently in urgent need. Strikingly, we reconfirmed the strong efficacy of our previously discovered antibody, JMB2002, against Omicron BA.2 in both binding assays and pseudovirus neutralization assay, with comparable inhibition potency to Omicron BA.1 strain. Further structural studies of JMB2002 Fab-bound Omicron BA.2 spike trimer enabled us to propose the inhibition mechanism of JMB2002 against Omicron BA.2, which is similar to the inhibition of Omicron BA.1 by JMB2002. As for Omicron BA.1, structural analysis reveals that the binding of JMB2002 (IgG or Fab) to the BA.2 spike trimer can completely block ACE2 binding, thus providing the basis for inhibition of both Omicron BA.1 and BA.2 variants by JMB2002.
In addition, our results also provided a possible origin host for Omicron BA.1 and BA.2. As reported, Omicron variants evolved independently of all other VOCs and its origin is a mystery.3 Investigation on the origin of Omicron BA.1 and BA.2 is critical for the effective control and prevention of COVID-19 in the human population. Mutation profile analysis suggests that the Omicron variants may have arisen through evolution via mouse host.4 In this study, our biochemical data confirmed that both BA.1 and BA.2 spike trimers are able to bind with high affinity to mouse ACE2 and cat ACE2, while the original WT spike binds well to cat ACE2 but not to mouse ACE2, indicating high susceptibility of mouse and cat to BA.1 and BA.2 infections (Fig. 7c). We determined the structures of spike trimers from both BA.1 and BA.2 in complex with mouse ACE2, and our structures elucidated that the three residue mutations Q493R, Q498R, and N501Y are essential for mACE2 binding, suggesting their importance in infections. Intriguingly, mutations on these three residues Q493, Q498, and N501, were detected in the mouse-adapted SARS-CoV-2.33,34,35 The Q498R and Q493R mutations were detected in mouse-adapted SARS-CoV-2 by passage 10 and passage 20, respectively, and have not since been detected in any SARS-CoV-2 variants from other animals.36 Based on our data reported here, combined with previous studies, we propose that mouse is a possible host for evolution of Omicron variants.
Taken together, our data reveal structural and biochemical insights into the enhanced transmissibility and antibody inhibition of Omicron BA.2 as well as a possible evolutionary pathway for Omicron variants. We propose that a prototype Omicron variant may have passed from human to cat, then to mouse, after some level of evolution in mouse, and then back to human (Fig. 7c). Although such an evolution pathway is highly speculative, the ability for Omicron variants to infect and spread in mice and possibly other animals could have important implications in the establishment of control strategy in combating SARS-CoV-2 infection.37,38
Materials and methods
The N-terminal peptidase domain (aa19-615) of ACE2 coding sequences of ACE2 from species of (human ACE2: NP _001358344.1; mouse ACE2 aa 19-615: NM _001130513.1; cat ACE2 aa 19-615: NP _001034545.1; rat ACE2: NP_001012006.1; dog ACE2 aa 19-615: NP _001158732.1; horse ACE2 aa 19-615: XP_001490241.1; sheep ACE2 aa 19-615: NP_001277036.1; pig ACE2 aa 19-615: NP_001116542.1) were optimized to Spodoptera frugiperda 9, and synthesized and cloned into the pFast-Bac-1 vector with an N-terminal GP67 signal peptide for secretion and a C-terminal 8 × His tag. The coding sequences of the anti-Fab nanobody were cloned into the PMESy4 plasmid with an N-terminal PelB signal peptide and a C-terminal 6 × His tag. All constructs were generated using Phanta Max Super-Fidelity DNA Polymerase (Vazyme Biotech Co., Ltd) and verified by DNA sequencing (Genewiz).
Protein expression and purification
The expression and purification of human ACE2 protein was carried out as described previously.3 Briefly, Hi5 cells were cultured in ESF 921 serum-free medium (Expression Systems) to a density of 3 million cells/mL and then infected with baculoviruses for ACE2 at a multiplicity of infection (m.o.i.) of about 5. After 60 h of infection, the supernatant containing ACE2 was clarified by centrifugation. The secreted peptidase domain of hACE2 was captured by Ni-NTA agarose (Smart-Lifesciences) and eluted with 300 mM imidazole in HBS buffer containing 25 mM HEPES pH 7.4, 150 mM sodium chloride. The hACE2 proteins were then purified by gel filtration chromatography using a Superdex 200 column (GE Healthcare) pre-equilibrated with HBS buffer. The fractions for hACE2 were collected, concentrated to approximately 2 mg/mL, and stored at –80 °C until use. Expression and purification of the other ACE2 proteins were performed in the same protocol as for human ACE2.
The SARS-CoV-2 spike ECD and RBD proteins were all purchased from Sino Biological Inc., including Omicron BA.1 spike ECD trimer (Cat: 40589-V08H26: containing furin cleavage site mutants and 2 P mutants, i.e., R682G, R683S, R685S, K986 P, and V987P), Omicron BA.2 spike ECD trimer (Cat: 40589-V08H28: with furin cleavage site mutants and 6 P mutants, that is R682G, R683S, R685S, F817P, A892P, A899P, A942P, K986P and V987P), WT spike ECD trimer (Cat: 40589-V08H8: containing D614G mutants, furin cleavage site mutants and 6P mutants, that is D614G, R682G, R683S, R685S, F817P, A892P, A899P, A942P, K986P, and V987P), According to Sino Biological’s description, all three ECD proteins were expressed with the bacteriophage T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus.
JMB2002 is a fully human IgG1 antibody, which contains N297A mutation in its constant region to attenuate Fc function. JMB2002 used in this study was expressed in CHO-K1 cell line and produced by WuXi Biologics (Shanghai, China). JMB2002 Fab was transiently expressed in CHO-K1 cells and purified by Ni-NTA column via 6xHis-tag fused to the C-terminal of heavy chain (Biointron, Taizhou, China).
The anti-Fab nanobody was expressed and purified as previously described.3 Briefly, the nanobodies were expressed in the periplasm of E. coli strain BL21(DE3) bacteria (NEB). Cultures of 2 L cells were grown to an OD600 = 0.8 at 37 °C and 180 rpm in 2× YT media containing 100 μg/mL ampicillin. Subsequently, 0.1 mM IPTG was added to the medium to induce protein expression at 28 °C and 180 rpm for an additional 8 h. Cells were harvested by centrifugation (5316 × g, 30 min) and disturbed in ice-cold buffer (20 mM HEPES pH 7.4, 100 mM NaCl), then centrifuged to remove cell debris. Nb was purified by nickel affinity chromatography as previously described, followed by size exclusion chromatography using a HiLoad 16/600 Superdex 75 column. Selected fractions of Nb were finally concentrated with 10% glycerol to ~2 mg/mL and rapidly frozen in liquid nitrogen and stored at −80 °C for further use. The quality of the purified proteins was assessed by SDS-PAGE.
Protein complex formation
For the ACE2 bound Omicron spike ECD protein complex, Omicron BA.1 or BA.2 spike ECD protein was incubated with the purified peptidase domain of human or mouse ACE2 at a molar ratio of 1:5 (spike trimer to peptidase domain of human ACE2) for 60 min on ice before purification by gel filtration chromatography using a Superose 6 increase 10/300 GL column (GE Healthcare) pre-equilibrated with TBS buffer (20 mM Tris, pH8.0, 150 mM NaCl). For the JMB2002 Fab bound Omicron spike ECD protein complex, the Omicron spike ECD protein was mixed with JMB2002Fab and anti-Fab nanobody in a molar ratio of 1:5:6 (spike trimer to JMB2002Fab to anti-Fab nanobody) was incubated on ice for 60 mins before purification by gel filtration chromatography using a Superose 6 increase 10/300 GL (GE Healthcare) incubated with HBS buffer (25 mM HEPES, pH 7.5, 150 mM NaCl). Fractions containing the complex were pooled and concentrated to 2 mg/mL.
Cryo-EM data collection
Cryo-EM grids were prepared with the Vitrobot Mark IV plunger (FEI) set to 4 °C and 100% humidity. Three-microliter of the sample was applied to the glow discharged gold R1.2/1.3 holey carbon grids. The sample was incubated for 10 s on the grids before blotting for 3 s (double-sided, blot force −2) and flash-frozen in liquid ethane immediately.
For Omicron BA.2 spike trimer-hACE2 complex, Omicron BA.2 spike trimer-JMB2002 antibody complex, Omicron BA.2 spike trimer-mACE2 complex, and Omicron BA.1 spike trimer-mACE2 complex datasets, 16107, 22686, 7071, and 6545 movies were collected respectively on a Titan Krios equipped with a Gatan K3 direct electron detection device at 300 kV with a magnification of 105,000, corresponding to a pixel size 0.824 Å. Image acquisition was performed with EPU Software (FEI Eindhoven, Netherlands). We collected a total of 36 frames accumulating to a total dose of 50 e−Å−2 over 2.5 s exposure.
Cryo-EM image processing
MotionCor2 was used to perform the frame-based motion-correction algorithm to generate drift-corrected micrograph for further processing and CTFFIND4 provided the estimation of the contrast transfer function (CTF) parameters.39,40 All subsequent steps including particle picking and extraction, 2D classification, three-dimensional (3D) classification, 3D refinement, and local refinement were performed using cryoSPARC,41 unless stated otherwise.
For Omicron BA.2 spike trimer-hACE2 complex dataset, a total of 3,411,860 particles were extracted from the cryo-EM micrographs. Two rounds of reference-free 2D classification, yielding 944,167 particles after clearance. Three rounds hetero refinement separated out 84,219 particles that resulted to a density of spike trimer-hACE2 structure (3:3 molar ratio) at 3.48 Å global resolution and 115,739 particles that resulted to a density of spike trimer-hACE2 structure (3:2 molar ratio) at 3.38 Å global resolution. Local refinement focused on the RBD-hACE2 with mask could reconstitute RBD-hACE2 structure at 3.00 Å global resolution.
For Omicron BA.2 spike trimer-JMB2002 antibody complex dataset, a total of 4,623,613 particles were extracted from the cryo-EM micrographs. Two rounds of reference-free 2D classification, yielding 819,158 particles after clearance. Three rounds hetero refinement separated out 326,802 particles that resulted to a density of spike trimer-Fab structure (3:3 molar ratio) at 3.27 Å global resolution.
For Omicron BA.2 spike trimer-mACE2 complex dataset, a total of 1,464,878 particles were extracted from the cryo-EM micrographs. Two rounds of reference-free 2D classification, yielding 537,614 particles after clearance. Three rounds hetero refinement separated out 170,078 particles that resulted to a density of spike bound to one mACE2 at 3.20 Å global resolution and 99,787 particles that resulted to a density of spike bound to two mACE2 at 3.30 Å global resolution. Local refinement focused on the RBD-ACE2 with mask could reconstitute BA.2 RBD-mACE2 structure at 3.01 Å global resolution.
For Omicron BA.1 spike trimer-mACE2 complex dataset, a total of 2,260,477 particles were extracted from the cryo-EM micrographs. Two rounds of reference-free 2D classification, yielding 1,675,669 particles after clearance. Three rounds hetero refinement separated out 227,749 particles that resulted to a density of spike bound to one mACE2 at 3.13 Å global resolution and 123,465 particles that resulted to a density of spike bound to two mACE2 at 3.24 Å global resolution. Local refinement focused on the RBD-mACE2 with mask could reconstitute BA.1 RBD-mACE2 structure at 2.60 Å global resolution.
Local resolution estimate was performed with cryoSPARC.
BA.1 spike trimer and hACE2 derived from PDB entry 7WPA structure and structure of mACE2 from Swiss-model prediction were used as the starting reference model for the building.42 All models were fitted into the EM density map using UCSF Chimera43 followed by iterative rounds of manual adjustment and automated rebuilding in COOT44 and PHENIX,45 respectively. The model was finalized by rebuilding in ISOLDE46 followed by refinement in PHENIX with torsion-angle restraints to the input model. The final model statistics were validated using Comprehensive validation (cryo-EM) in PHENIX.45 All structural figures were prepared using Chimera,43 ChimeraX,47 and PyMOL (Schrödinger, LLC.).
Thermal shift assay (TSA)
The spike ECD proteins of Omicron BA.1, BA.2, and WT SARS -CoV-2 were diluted to 0.5 mg/ml with 200 mM HEPES pH 7.4, 150 mM sodium chloride (final HEPES concentration: 100 mM). Then, the diluted proteins were mixed with 10× SYPRO Orange (Thermo Fisher) and incubated for 10 min at room temperature. The reaction was performed in 384-well plates with a final volume of 10 μL. The thermal melting curves were monitored from 25 °C to 80 °C using a LightCycler 480 II Real-Time PCR System (Roche Diagnostics) with a ramp rate of 3.6 °C per minute from 25 °C to 80 °C. Melting peaks were calculated by the LightCycler 480 software from Roche Diagnostics. A representative figure from triple experiments is shown.
Measurement of dimeric human ACE2 binding to Omicron BA.1, Omicron BA.2, and WT SARS-CoV-2 spike ECD by biolayer interferometry
The interaction of dimeric human ACE2 with Omicron BA.1, Omicron BA.2, and WT SARS-CoV-2 spike ECD were evaluated using Octet Red96e (Sartorius). The dimeric human ACE2 (Sino Biological, 10108-H02H) was immobilized on Protein A biosensor (Sartorius, 18-5012) followed by measuring the association and dissociation with Omicron BA.1 (Sino Biological, 40589-V08H26), Omicron BA.2 (Sino Biological, 40589-V08H28) or WT SARS-CoV-2 spike ECD protein (ACRO, SPN-C52H9). KD values were calculated with Octet Data Analysis HT 12.0 software using a 1:1 global fit model. Data were plotted using Prism V8.0 software (GraphPad). One representative figure from two independent experiments is shown.
Measurement of anti-SARS-CoV-2 antibody JMB2002 binding to Omicron BA.2 SARS-CoV-2 spike ECD by biolayer interferometry
The binding of anti-SARS-CoV-2 antibody JMB2002 to Omicron BA.2 spike ECD was determined using Octet Red96e (Sartorius). The biotinylation of Omicron BA.2 spike ECD protein were performed using EZ-Link Sulfo-NHS-LC-Biotin kit (ThermoFisher Scientific, A39257) following the manufacturer’s instruction. SA biosensors (Sartorius, 18-5020) were used to capture the biotinylated Omicron BA.2 spike ECD protein. The interaction of Omicron BA.2 spike ECD protein-coated sensors with different concentrations of anti-SARS-CoV-2 antibody JMB2002 were recorded prior to dissociation in kinetics buffer (0.02% Tween-20 in PBS). KD values were calculated with Octet Data Analysis HT 12.0 software using a 1:1 global fit model. Data were plotted using Prism V8.0 software (GraphPad). One representative figure from two independent experiments is shown.
Pseudovirus neutralization assay
In the pseudovirus neutralization assay, serial dilutions of JMB2002 IgG were preincubated with an equal volume of Omicron BA.2 pseudovirus (2 × 104 TCID50/mL) for 1 h at 37 °C. Subsequently, HEK293 cells stably expressing hACE2 (Vazyme, DD1401) (2 × 104 cells/well) were seeded in 96-well plates followed by the addition of pseudovirus and antibody mixtures, and incubated at 37 °C for 48 h. Luciferase activity was measured using Bio-Lite Luciferase Assay System (Vazyme, DD1201). The neutralization inhibition rate was calculated using the following formula.
IC50 values were calculated by a four-parameter logistic curve fitting approach in Prism V8.0 software (GraphPad). One representative figure from two independent experiments is shown.
Measurement of monomeric ACE2 from different species interaction with Omicron BA.1, Omicron BA.2, and WT SARS-CoV-2 spike ECD by biolayer interferometry
The binding of monomeric human, murine, cat, and dog ACE2 to Omicron BA.1, Omicron BA.2, and WT SARS-CoV-2 spike ECD were evaluated using Octet Red96e (Sartorius). The monomeric ACE2 of different species was biotinylated using EZ-Link Sulfo-NHS-LC-Biotin kit (ThermoFisher Scientific, A39257) following the manufacturer’s instruction. SA biosensors (Sartorius, 18-5020) were then used to immobilize the biotinylated monomeric ACE2 proteins. The association and dissociation of biotinylated monomeric human, murine, cat, and dog ACE2 with different concentrations of Omicron BA.1, Omicron BA.2, or WT SARS-CoV-2 spike ECD were recorded. KD values were calculated with Octet Data Analysis HT 12.0 software using a 1:1 global fit model. Data were plotted using Prism V8.0 software (GraphPad). One representative figure from two independent experiments is shown.
Materials are available from the corresponding authors upon reasonable request. Density maps and structure coordinates have been deposited in the Electron Microscopy Data Bank (EMDB) and the Protein Data Bank (PDB) with accession codes EMD-33336 and PDB ID 7XO4 for BA.1 spike trimer in complex with two mouse ACE2s; EMD-33337 and PDB ID 7XO5 for BA.1 spike trimer in complex with one mouse ACE2; EMD-33338 and PDB ID 7XO6 for BA.1 RBD in complex with one mouse ACE2; EMD-33339 and PDB ID 7XO7 for BA.2 spike trimer in complex with two human ACE2s; EMD-33340 and PDB ID 7XO8 for BA.2 spike trimer in complex with three human ACE2s; EMD-33341 and PDB ID 7XO9 for BA.2 RBD in complex with one human ACE2; EMD-33342 and PDB ID 7XOA for BA.2 spike trimer in complex with one mouse ACE2; EMD-33343 and PDB ID 7XOB for BA.2 spike trimer in complex with two mouse ACE2s; EMD-33344 and PDB ID 7XOC for BA.2 RBD in complex with one mouse ACE2; and EMD-33345 and PDB ID 7XOD for Omicron BA.2 spike trimer in complex with three JMB2002 Fabs.
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet. Infect. Dis. 20, 533–534 (2020).
Genomic epidemiology of SARS-CoV-2 with global subsampling, https://nextstrain.org/ncov/ (2022).
Yin, W. et al. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. Science 375, 1048–1053 (2022).
Sun, Y., Lin, W., Dong, W. & Xu, J. Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. J. Biosaf. Biosecur. 4, 33–37 (2022).
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).
Wu, C. R., Yin, W. C., Jiang, Y. & Xu, H. E. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol. Sin. https://doi.org/10.1038/s41401-021-00851-w (2022).
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020).
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894–904.e9 (2020).
Xu, C. et al. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci. Adv. 7, (2021).
Fan, X., Cao, D., Kong, L. & Zhang, X. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. Nat. Commun. 11, 3618 (2020).
Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182, 73–84.e16 (2020).
Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108 (2021).
Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219.e32 (2021).
Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).
Xu, J. et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 595, 278–282 (2021).
Li, Q. et al. Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm (2020) 3, e130 (2022).
Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860–871.e13 (2022).
Han, P. et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 185, 630–640.e10 (2022).
Hong, Q. et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546–552 (2022).
Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700–705 (2022).
Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell https://doi.org/10.1016/j.cell.2022.04.035 (2022).
Gu, C. et al. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. mAbs 13, 1930636 (2021).
Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).
Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N. Engl. J. Med. 386, 1579–1580 (2022).
Wu, L. et al. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov. 6, 68 (2020).
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-022-01792-5 (2022).
Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
Huang, K. et al. Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine 67, 103381 (2021).
Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070–1085.e12 (2020).
Wong, L. R. et al. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146–151 (2022).
Chandler, J. C. et al. SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus virginianus). Proc. Natl. Acad. Sci. USA 118, e2114828118 (2021).
Hale, V. L. et al. SARS-CoV-2 infection in free-ranging white-tailed deer. Nature 602, 481–486 (2022).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Schwede, T., Kopp, J., Guex, N. & Peitsch, M. C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 31, 3381–3385 (2003).
Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Adams, P. D. et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Synchrotron Radiat. 11, 53–55 (2004).
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D Struct. Biol. 74, 519–530 (2018).
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
The cryo-EM data of the Omicron spike protein complexes were collected at the Shanghai Advanced Electron Microscope Center, Shanghai Institute of Material Medica. This work was partially supported by Ministry of Science and Technology (China) grants (2018YFA0507002 to H.E.X.); Shanghai Municipal Science and Technology Major Project (2019SHZDZX02 to H.E.X.); Shanghai Municipal Science and Technology Major Project (H.E.X.); CAS Strategic Priority Research Program (XDB37030103 to H.E.X.), the National Natural Science Foundation of China (32130022 to H.E.X.); the Youth Innovation Promotion Association of CAS (2021278 to W.Y.); the National Natural Science Foundation of China (32171189 to W.Y.); the National Science Fund for Excellent Young Scholars (82122067 to W.Y.); Key tasks of the Lingang Laboratory (LG202103-03-05 to W.Y.); Key tasks of Lingang Laboratory (LG202101-01-03 to Y.X.); the National Natural Science Foundation of China (81902085 to Y.X.); China Postdoctoral Science Foundation Funded Project (2021M703342 to C.W.); Shanghai Post-doctoral Excellence Program (2021429 to C.W.). In addition, this work was partially supported by High-level new R&D institute (2019B090904008), and High-level Innovative Research Institute (2021B0909050003) from Department of Science and Technology of Guangdong Province, and the author W.Y. also gratefully acknowledges the support of Sanofi Scholarship Program.
H.E.X., W.Y., Y.X., C.W., H.L., M.J., X.X.W., Q.Y., and K.W. have declared no competing interest. S.-J.D., X.C., C.G., J.L., D.W., X.H., and X.P.W., are employees of Shanghai Jemincare Pharmaceuticals Co. Ltd., and are developing JMB2002 as a potential anti-Omicron therapeutic.
About this article
Cite this article
Xu, Y., Wu, C., Cao, X. et al. Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins. Cell Res 32, 609–620 (2022). https://doi.org/10.1038/s41422-022-00672-4
Signal Transduction and Targeted Therapy (2022)
Cell Research (2022)